Article information
Full text is only aviable in PDF
Bibliografía
[1.]
P.J. Sterk, S.A. Buist, A.J. Woolcock, et al.
The message from the World Asthma Meeting.
Eur Respir J, 14 (1999), pp. 1435-1453
[2.]
K.J. Haley, J.M. Drazen.
Inflammation and airway function in asthma What you see is not necessarily what you get..
Am J Respir Crit Care Med, 157 (1998), pp. 1-3
[3.]
Global Initiative for, Asthma.
Global Strategy for Asthma Management and Prevention NHLBI/WHO Workskop Report National Institutes of Health.
Publication n.o, 95 (1995), pp. 3659
[4.]
National Asthma Education, Prevention, Program.
Expert PanelReport II: Guidelines for the Diagnosis and Management of Asthma Bethesda: National Institutes of Health.
Publication n.o, 97 (1997), pp. 4051
[5.]
Sociedad Española de Neumología, Cirugía Torácica, Sociedad Española de Medicina de Familia, Comunitaria.
Recomendaciones para la atención del paciente con asma.
Arch Bronconeumol, 34 (1998), pp. 394-398
[6.]
G.L. Colice, V. Vanden Burgt, J. Song, P. Stampone, P.h.J. Thompson.
Categorizing asthma severity..
Am J Respir Crit Care Med, 160 (1999), pp. 1962-1967
[8.]
E.F. Junniper, P.M. O’Byrne, G.H. Guyatt, P.J. Ferrie, D.R. King.
Development and validation of a questionnaire to measure asthma control.
Eur Respir J, 14 (1999), pp. 902-907
[9.]
J.K. Sont, L.N.A. Willems, E.H. Bel, J.H.J.M. Van Krieken, J.P. Vandenbroucke, P.J. Sterk, et al.
Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment.
Am J Respir Crit Care Med, 159 (1999), pp. 1043-1051
[10.]
A. Jatakanon, S. Lim, P.J. Barnes.
Changes in sputum eosinophils predict loss of asthma control.
Am J Respir Crit Care Med, 161 (2000), pp. 64-72
[11.]
C. Pellicer, P. Lorente, P. Valero, M.J. Cremaes, J. Fullana, M. Perpiñá, et al.
Estudio descriptivo de los pacientes diagnosticados de asma en una consulta neumológica de ámbito comarcal.
Arch Bronconeumol, 35 (1999), pp. 167-199
[12.]
M.J. Espinosa de los Monteros, A. González, F. Rodríguez, R. Gabriel, J. Ancoechea.
Análisis descriptivo (características clínicas y funcionales) de la población asmática de un área sanitaria.
Arch Bronconeumol, 35 (1999), pp. 518-524
[13.]
A.P. Greening, Ph.W. Ind, M. Northfield, G. Shaw, et al.
Added salmeterol versus higher-dose corticosteroids in asthma patients with symptoms on existing inhaled corticosteroid.
Lancet, 344 (1994), pp. 219-224
[14.]
A. Woolcock, B. Lunback, N. Ringdal, L.A. Jacques.
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.
Am J Respir Crit Care Med, 153 (1996), pp. 1481-1488
[15.]
A.A.P.H. Verbene, C. Frost, R.J. Roorda, H. Van der Laag, K.F. Kerrebijn, et al.
One year treatment with salmeterol compared with beclmethasone in children with asthma.
Am J Respir Crit Care Med, 156 (1997), pp. 688-695
[16.]
A.A.P.H. Verbene, C. Frost, E.J. Duiverman, M.H. Grol, K.F. Kerrebijn, et al.
Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma.
Am J Respir Crit Care Med, 158 (1998), pp. 213-219
[17.]
E.J.M. Weersink, R.R. Douma, D.S. Postma, G.H. Koëter.
Fluticasone propionate, salmeterol, xinafoate, and their combination in the treatment of nocturnal asthma.
Am J Respir Crit Care Med, 155 (1997), pp. 1241-1246
[18.]
R.A. Pauwels, C.G. Löfdahl, D.S. Postma, A.E. Tattersfield, P. O’Byrne, P.J. Barnes, et al.
Effect of inhaled formoterol and budesonide on exacerbations of asthma.
N Engl J Med, 337 (1997), pp. 1405-1411
[19.]
E.F. Junniper, K. Svensson, P.M. O’Byrne, P.J. Barnes, C.A. Bauer, C.G.A. Löfdahl, et al.
Asthma quality of life during 1 year of treatment with budesonide with or without formoterol.
Eur Respir J, 14 (1999), pp. 1038-1043
[20.]
J.A. Van Noord, A.J.M. Schreurs, S.J.M. Mol, P.G.H. Mulder.
Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma.
Thorax, 54 (1999), pp. 207-212
[21.]
D.S. Pearlman, W. Stricker, S. Weinstein, G. Gross, P. Chervinsky, A. Woodring, et al.
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Ann Allergy Asthma Immunol, 82 (1999), pp. 257-265
[22.]
J.J. Condemi, S. Goldstein, C. Kalberg, S. Yancey, A. Emmett, K. Rickard, et al.
The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma.
Ann Allergy Asthma Immunol, 82 (1999), pp. 383-389
[23.]
G. Shapiro, W. Lumry, J. Wolfe, J. Given, M.V. White, A. Woodring, et al.
Combined salmeterol 50 mcg and fluticasone propionate 250 mcg in th diskus device for the treatment of asthma.
Am J Respir Crit Care Med, 161 (2000), pp. 527-534
[24.]
K.F. Chung.
The complementary role of glucocorticosteroids and long-acting beta adrenergic agonists..
Alergy, 53 (1998), pp. 7-13
[25.]
R.H. Moore, A. Khan, B.F. Dickey.
Long-acting inhaled beta2-agonists in asthma therapy..
Chest, 113 (1998), pp. 1095-1108
[26.]
L.-P. Boulet, A. Cartier, J. Milot, J.-L. Malo, M. Laviolette.
Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticoids.
Eur Respir J, 11 (1998), pp. 1091-1097
[27.]
S. Durham.
Long-acting inhaled beta2-agonists: anti-inflammatory effects not evident during treatment of day today asthma.
Eur Respir J, 14 (1999), pp. 249-250
[28.]
A.J. Roberts, P. Bradding, K.M. Britten, A.F. Walls, S. Wilson, C. Gratziou, et al.
The long-acting beta2-agonist salmeterol xinofoiate: effects on airway inflammation in asthma.
Eur Respir J, 14 (1999), pp. 275-282
[29.]
L.P. Nielsen, B. Pedersen, P. Faurschou, F. Madsen, J.T.R. Wilcke, R. Dahl.
Salmeterol reduces the need for inhaled corticosteroids in steroid-dependent asthmatics.
Respiration, 93 (1999), pp. 863-868
[30.]
J.C. Kips, B.J. O’Connor, M.D. Inman, K. Svensson, R.A. Pauwels, P.M. O’Byrne.
A long-term study of the antiinflammatory effect of lowe-dose budesonide plus formoterol versus high-dose budesonide in asthma.
Am J Respir Crit Care Med, 161 (2000), pp. 996-1001
[31.]
R.A. Mc Ivor, E. Pizzichini, M.O. Turner, P. Hussack, F.E. Hargreave, M.R. Sears.
Potential masking effects of salmeterol on airway inflammation in asthma.
Am J Respir Crit Care Med, 158 (1998), pp. 924-930
[32.]
G.P. Anderson.
Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation.
Am J Respir Crit Care Med, 161 (2000), pp. 188S-196S
Copyright © 2000. Sociedad Española de Neumología y Cirugía Torácica
